The global newborn screening market is projected to grow from USD 977.83 million in 2025 to USD 1,882.59 million by 2034, at a CAGR of 7.55%. Growth is driven by rising birth rates, increasing prevalence of neonatal disorders, and government initiatives for early diagnosis. Asia Pacific leads with the largest share, while North America is expected to see the fastest growth.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Newborn Screening Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Newborn Screening Market, by Product
8.1.1 Instruments
8.1.1.1. Market Revenue and Forecast
8.1.2. Reagents
8.1.2.1. Market Revenue and Forecast
9.1. Newborn Screening Market, by Technology
9.1.1. Tandem Mass Spectrometry
9.1.1.1. Market Revenue and Forecast
9.1.2. Pulse Oximetry
9.1.2.1. Market Revenue and Forecast
9.1.3. Enzyme Based Assay
9.1.3.1. Market Revenue and Forecast
9.1.4. DNA Assay
9.1.4.1. Market Revenue and Forecast
9.1.5. Electrophoresis
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Newborn Screening Market, by Test Type
10.1.1. Dry Blood Spot Test
10.1.1.1. Market Revenue and Forecast
10.1.2. CCHD
10.1.2.1. Market Revenue and Forecast
10.1.3. Hearing Screen
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by Technology
11.1.3. Market Revenue and Forecast, by Test Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Technology
11.1.4.3. Market Revenue and Forecast, by Test Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by Technology
11.1.5.3. Market Revenue and Forecast, by Test Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by Technology
11.2.3. Market Revenue and Forecast, by Test Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by Technology
11.2.4.3. Market Revenue and Forecast, by Test Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by Technology
11.2.5.3. Market Revenue and Forecast, by Test Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by Technology
11.2.6.3. Market Revenue and Forecast, by Test Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by Technology
11.2.7.3. Market Revenue and Forecast, by Test Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by Technology
11.3.3. Market Revenue and Forecast, by Test Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by Technology
11.3.4.3. Market Revenue and Forecast, by Test Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by Technology
11.3.5.3. Market Revenue and Forecast, by Test Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by Technology
11.3.6.3. Market Revenue and Forecast, by Test Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by Technology
11.3.7.3. Market Revenue and Forecast, by Test Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by Technology
11.4.3. Market Revenue and Forecast, by Test Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by Technology
11.4.4.3. Market Revenue and Forecast, by Test Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by Technology
11.4.5.3. Market Revenue and Forecast, by Test Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by Technology
11.4.6.3. Market Revenue and Forecast, by Test Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by Technology
11.4.7.3. Market Revenue and Forecast, by Test Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by Technology
11.5.3. Market Revenue and Forecast, by Test Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by Technology
11.5.4.3. Market Revenue and Forecast, by Test Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by Technology
11.5.5.3. Market Revenue and Forecast, by Test Type
12.1. Bio-Rad Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agilent Technologies
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Waters Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Natus Medical
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Trivitron Healthcare
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. GE Lifesciences
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. PerkinElmer Inc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AB SCIEX
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Covidien plc
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Masimo
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description